European association involved in the research and care of children with neuroblastoma - SIOPEN

Surgery

The surgeon committee’s major achievement this year was a SIOPEN, COG and GPOH initiative leading to the implementation of an international standard for systematic surgery report for neuroblastoma as a (e-CRF). This report consists of three sections (general information, intraoperative details including IDRFs and complications). Our aim is for it to included in the new high-risk protocol and completed on line prospectively, by the surgeon him/herself, or the referent surgeon of the country. The current plan is to disseminate this form and to evaluate its feasibility and usefulness in the future protocols. This initiative will be presented at SIOP 2018 to raise awareness of this international collaboration.

After a short survey on the practice of minimally invasive surgery in neuroblastoma treatment, a larger study was performed collecting 279 patients over 7 countries and 19 centers. 30% presented at least one IDRF. Complete or near complete resection was achieved in 83% of cases, conversion occurred in 9% and surgical- related morbidity in 11%. The paper will be presented in the next SIOP meeting.

 

Finally a work still ongoing aimed at evaluate the influence of residues on the outcome of HR patients in 13 centers from 8 countries. All the post-operative imaging (66% CT scan) were reviewed. Residue was present in 47% of cases but was of very low volume, under 5 ml in 80% of cases and did not seem to influence OS and EFS.

 

Aims of group

  1. to disseminate the surgical e-CRF as widely as possible in order to ensure the quality of the surgical data entered in the new HRNBL2;
  2. to be able to study the outcome according to quality of resection and surgical related morbidity;
  3. to access to the QUARTET platform in order to share imaging in difficult cases raised by the new HR protocol
  4. to analyze the data of the LINES protocol in order to be able to re-stratify IDRFs after chemotherapy and to identify which patients may benefit from surgery after chemotherapy in the groups where the indication of surgery was left pending if IDRFs remain positive.

 

 

Publications

Avanzini S, Pio L, Erminio G, Granata C, Holmes K, Gambart M, Buffa P, Castel V, Valteau Couanet D, Garaventa A, Pistorio A, Cecchetto G, Martucciello G, Mattioli G, Sarnacki S. Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes. Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26605. Epub 2017 Apr 25.

Valteau-Couanet D, Schleiermacher G, Sarnacki S, Pasqualini C. High-risk neuroblastoma treatment strategy: The experience of the SIOPEN group. Bull Cancer. 2018 Oct 2. pii: S0007-4551(18)30278-9. doi: 10.1016/j.bulcan.2018.09.002. [Epub ahead of print] Review. French.

Communications

Implementation of an international standard for systematic surgery report for neuroblastoma: a SIOPEN, COG and GPOH initiative.

CP Van de Ven, J.Nuchtern, L.Matthyssens, H.Gabra, S.Irtan, Jakob Stenman, Kristin Bjornland, Daphné Hompes, Luca Pio, K.Cross, Stefano Avanzini, Javier Gomez, P.Losty, J.Fuchs, M.LaQuaglia, D.Von Schweinitz, Sabine Sarnacki.
SIOP, Kyoto October 16th - 19th 2018
Minimally invasive surgery for Neuroblastic tumours, a SIOPEN international study.
Hany Gabra, Luca Pio, Sabine Irtan, Kate Cross, Pablo Lobbos, Marc-David Leclair, Stefano Avanzini, Girolamo Mattioli, Gabriela Guillén Burrieza, Steven Warmann, Aurélien Scalabre, Calogero Virgone, Francesco Fascetti-Leon, Javier Gómez Chacón Villalba, Michael Nightingale, Florent Guérin, Giovanna Riccipetitoni, Olivier Abbo, Jakob Stenman, Paul Losty, Yves Heloury, Sabine Sarnacki.
SIOP, Kyoto October 16th - 19th 2018

Radiological description and impact on outcome of postoperative residue after high-risk neuroblastoma surgery
S. Irtan, H. Ducou Le Pointe, C. Fayard, H. Gabra, C. Granata, S. Avanzini, L. Pio, J. Gomez-Chacon, S. Braungart, J. Stenman, F. Sundquist, J. Strömgren, D. Plantaz, L. Matthyssens, N. Jauquier, K. Bjornland, A. Ingegerd, K. Cross, K. McHugh, S. Sarnacki.
SIOP, Kyoto October 16th - 19th 2018

The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/cho immunotherapy in the hr-nbl1/siopen trial
R. Ladenstein, U. Poetschger, S. Sarnacki, T. Monclair, G. Cecchetto, J. Gomez-Chacon, J. Stenman, J. Joseph, R. Luksch, V. Castel, S. Ash, V. Papadakis, J. Malis, W. Balwierz, C. Owens, H. Lode, T. Boterberg, D. Valteau-Couanet, A. Pearson, K. Holmes.
ANR, San Francisco, May 9th - 12th, 2018

The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/cho immunotherapy in the hr-nbl1/siopen trial
R. Ladenstein, U. Poetschger, S. Sarnacki, T. Monclair, G. Cecchetto, J. Gomez-Chacon, J. Stenman, J. Joseph, R. Luksch, V. Castel, S. Ash, V. Papadakis, J. Malis, W. Balwierz, C. Owens, H. Lode, T. Boterberg, D. Valteau-Couanet, A. Pearson, K. Holmes.
SIOP, Kyoto October 16th - 19th 2018